Hematological Malignancies | Norton Healthcare

Indication: Hematological Malignancies

A Phase 2/3, Multicenter, Randomized, Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

Lymphoma

Sub-indication: Diffuse Large B-Cell Lymphoma

Line of Therapy: 2nd or 3rd Line

Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Karyopharm Therapeutics Inc.

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.